FDA Surprised By Device Manufacturer's Quick Consent Decree Turnaround
This article was originally published in The Silver Sheet
Executive Summary
WHEN A DEVICE MANUFACTURER ENTERS INTO A CONSENT DECREE with FDA, it often takes years to solve its quality systems problems and obtain clearance to begin selling its devices again. However, Custom Ultrasonics, a Pennsylvania maker of endoscope disinfection systems, worked through its consent decree in less than four months. “It's the fastest I've seen around here,” CDRH Compliance Director Tim Ulatowski says. Ulatowski says FDA will consider making more use of consent decrees rather than issuing multiple warning letters to companies. Legal experts discuss how firms should handle a consent decre
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.